Gina BartasiFounder

United States - New York, New York

Gina is the Founder and Executive Chairman of Kindbody, which is a technology-driven, fertility clinic network and family-building benefits solution for employers offering virtual and in-person care with 31 U.S. clinics with plans to open 11 more in 2023. Kindbody's clinically managed program includes fertility assessments, egg freezing, in vitro fertilization (IVF), genetic testing, donor and surrogacy services, and adoption, as well as physical, mental, and emotional support from preconception through postpartum. Kindbody is the trusted family-building benefits provider for 100+ blue-chip employers, covering more than 2.4 million lives. Many thousands more receive their fertility care directly from Kindbody throughout the country at its signature clinics, mobile clinics, and partner clinics. As the fertility benefits solution, technology platform, and direct provider of high-quality fertility care through its own signature clinics, Kindbody delivers a seamless, integrated experience with superior health outcomes at lower cost. Gina’s passion is to bring high-quality, affordable fertility care to all, rather than a privileged few. Kindbody has raised $230 million in debt and equity funding and anticipates continued rapid growth as more and more employers seek to reduce waste by eliminating the middleman and buying fertility services directly from providers.

Gina is the former Founder and CEO of Progyny (Nasdaq: PGNY) which went public October 25, 2019 at a $1.3B valuation and was valued at $6B in Nov 2021. In late 2014, Gina was recruited by life sciences investors at Kleiner Perkins and TPG to lead the turnaround of their medical device investment in Auxogyn’s Eeva (Early Embryo Viability Assessment) with the merger of her company, FertilityAuthority to form Progyny. During her two-year tenure, Gina simultaneously scaled Progyny's fertility benefits offering landing the largest tech employers in the world while proposing that Eeva be divested. Post Gina’s departure, the Eeva medical device was divested and sold by Progyny to Merck for $8M, including debt.